Liu Jean I reported grant involving 8,984 shares of Connect Biopharma Holdings Ltd at $0.00 for $0 on Sep 30, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Oct 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
8,984Ordinary Shares
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
20,763Direct
Trade date
Sep 30, 2026Grant
Filed
Oct 1, 2026, 5:17 PM ET1-day reporting delay
Accession
0001835268-26-000039Code A · Transaction 233141
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CNTB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CNTB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 8, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.